Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Keymed Biosciences Inc.
康諾亞生物醫藥科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2162)

VOLUNTARY ANNOUNCEMENT
SHARE PURCHASE PURSUANT TO THE 2022 RESTRICTED SHARE UNIT SCHEME

This announcement is made by Keymed Biosciences Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

In relation to the restricted share unit scheme adopted by the Company on January 21, 2022 (the "**2022 RSU Scheme**"), the Board wishes to announce that it has authorized the Company to instruct the independent professional trustee appointed for the administration of the 2022 RSU Scheme (the "**Trustee**") to purchase ordinary shares of the Company ("**Shares**") on the market at the prevailing market price (the "**Share Purchase**") utilizing approximately HK$100 million in accordance with the rules of the 2022 RSU Scheme and the trust deed. The Shares so purchased will be held by the Trustee on trust for the benefit of the grantees and used for the award of Shares (the "**Awards**") under the 2022 RSU Scheme.

The Board is of the view that the Shares are extremely undervalued at their current market price, which does not reflect the long-term value and growth potential of the Group. This presents a good opportunity to purchase Shares for future grants of Awards under the 2022 RSU Scheme. The Company remains firmly confident in the Group's long-term development. The Board believes that the on-market purchase of Shares will further support the grant of Awards under the 2022 RSU Scheme, align the interests of the grantees with those of the Company and its shareholders as a whole, and incentivize them to contribute to the sustainable long-term development of the Group, thereby providing sustained and strong momentum for the Group to maintain its leading position in the industry.

The purchased Shares will be held by the Trustee in accordance with the rules of the 2022 RSU Scheme and the terms of the trust deed entered into between the Company and the Trustee. Subject to and in accordance with the provisions of the 2022 RSU Scheme and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the Board or its authorized person(s) will from time to time review and determine in its absolute discretion the number of Shares to be granted to eligible persons with vesting conditions as the Board or its authorized person(s) may deem appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Keymed Biosciences Inc.
Dr. Bo CHEN
Chairman

Hong Kong, October 29, 2026

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Bo CHEN, Dr. Changyu WANG and Dr. Gang XU as executive Directors; Mr. Qi CHEN and Mr. Yilun LIU as non-executive Directors; and Prof. Xiao-Fan WANG, Prof. Yang KE and Mr. Cheuk Kin Stephen LAW as independent non-executive Directors.